Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
Biomind Labs Announces CAD $2.52 Million Private Placement Financing
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs Announces Revocation of Cease Trade Order
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board